|
|
News Breaks | | | | August 7, 2012 | | 08:42 EDT |  | MR | Mindray Medical reported outstanding Q2 results, says Oppenheimer
After Mindray reported higher than expected Q2 revenue and increased its net income guidance, Oppenheimer maintains a $34 target and Outperform rating on the stock. | |
|
News For MR From The Last 14 Days Check below for free stories on MR the last two weeks. |
|
|
| There are no results for MR |
|
|
|
|
|
|
